Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bordeaux
Clinical trial register · France

Clinical Trials in Bordeaux, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 64 Bordeaux 62 Montpellier 61 Lyon 60 Marseille 58
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Bordeaux126 AstraZeneca62 Assistance Publique - Hôpitaux de Paris44 UNICANCER40 Novartis Pharmaceuticals35 Clear sponsor filter
Site location
Paris64 Bordeaux62 Montpellier61 Lyon60 Marseille58
All 106 locations
Target enrolment
to

Trials with a site in Bordeaux

62 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
AstraZeneca
Phase 3
1,072
Bordeaux, Paris, Strasbourg, Toulouse
2026-08-31
Recruiting
AstraZeneca
Phase 3
915
Bordeaux, Montpellier, Paris, Pierre-Bénite, Poitiers, Strasbourg
2026-07-16
Recruiting
AstraZeneca
Phase 2
43
Bordeaux, Créteil, Lyon, Nantes, Nîmes
2026-03-28
Recruiting
AstraZeneca
Phase 3
2,130
Bordeaux, Caen, Lyon, Marseille, Rennes, Villejuif
2026-02-03
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bordeaux, Dijon, Limoges, Marseille, Nantes, Nice, Paris
2025-11-24
Active, closed
AstraZeneca
Phase 3
212
Amiens, Bois-Guillaume, Bordeaux, Lille, Paris
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Angers, Bordeaux, Caen, Clermont-Ferrand, Le Mans, Marseille, Montpellier, Nice
2025-08-06
Recruiting
AstraZeneca
Phase 3
800
Avignon, Besançon, Bordeaux, Chambray-lès-Tours, Cholet, Créteil, Grenoble, Lille
2025-08-01
Recruiting
AstraZeneca
Phase 3
15,100
Bordeaux, Brest, Bron, Corbeil-Essonnes, Dijon, La Tronche, Lille, Limoges
2025-06-04
Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab
AstraZeneca
Phase 2
150
Angers, Bordeaux, Chambray-lès-Tours, Dijon, Lille, Lyon, Marseille, Montpellier
2025-05-15
Recruiting
AstraZeneca
Phase 1
72
Bordeaux, Montpellier, Nancy, Paris, Strasbourg, Toulouse
2025-05-01
Recruiting
AstraZeneca
Phase 3
600
Besançon, Bordeaux, Caen, Clermont-Ferrand, Lyon, Montpellier, Nice, Paris
2025-03-27
Recruiting
AstraZeneca
Phase 3
5,000
Amiens, Bordeaux, Boulogne-Billancourt, Brest, Clermont-Ferrand, Créteil, La Roche-sur-Yon, Le Mans
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Bordeaux, Caen, Clermont-Ferrand, Dijon, Lyon, Marseille, Poitiers, Rennes
2025-03-01
Active, closed
AstraZeneca
Phase 3
768
Bordeaux, Caen, Lille, Montpellier, Nantes, Paris, Pessac, Toulon Armees
2024-10-04
Active, closed
AstraZeneca
Phase 3
2,554
Amiens, Annonay, Bois-Guillaume, Bordeaux, Boulogne-Billancourt, Brest, Clermont-Ferrand, La Roche-sur-Yon
2024-03-29
Recruiting
AstraZeneca
Phase 3
100
Bordeaux, Bron, Le Kremlin-Bicêtre, Lille, Toulouse
2024-03-14
Recruiting
AstraZeneca
Phase 3
1,145
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
2023-12-14
Active, closed
AstraZeneca
Phase 3
1,898
Angers, Bayonne, Bordeaux, Caen, Clermont-Ferrand, Créteil, Lyon, Montpellier
2023-11-21
Active, closed
AstraZeneca
Phase 3
314
Bordeaux, Brest, Paris, Rennes, Strasbourg, Toulouse
2023-11-08
Active, closed
AstraZeneca
Phase 3
895
Angers, Avignon, Bayonne, Bordeaux, Caen, Lille, Limoges, Marseille
2023-10-24
Active, closed
PRostate Olaparib Real World Evidence Study
NCT06031805Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Observational
159
Amiens, Angers, Antony, Argenteuil, Avignon, Besançon, Bordeaux, Challes-les-Eaux
2023-10-11
Active, closed
AstraZeneca
Phase 3
5,511
Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Epagny Metz-Tessy, Lille, Lyon
2023-10-05
Recruiting
AstraZeneca
Phase 3
4,300
Angers, Argenteuil, Avignon, Bordeaux, Bourg-en-Bresse, Caen, Cholet, Clermont-Ferrand
2023-03-31
Active, closed
AstraZeneca
Observational
551
Nice, Clermont-Ferrand, Strasbourg, Finist Re, Dijon, Bordeaux, Grenoble, Saint-Denis
2023-02-27
Active, closed
AstraZeneca
Phase 3
1,174
Angers, Bordeaux, Dijon, Lyon, Montpellier, Nîmes, Paris, Poitiers
2022-11-28
Active, closed
AstraZeneca
Observational
254
Angers, Argenteuil, Avignon, Bayonne, Bordeaux, Clermont-Ferrand, Créteil, Dijon
2022-11-14
Recruiting
AstraZeneca
Phase 2
454
Bordeaux, Lyon, Marseille, Suresnes
2022-09-06
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Amiens, Angers, Bordeaux, Lille, Lyon, Marseille, Paris, Rennes
2022-05-23
Active, closed
AstraZeneca
Phase 3
644
Bordeaux, Dijon, Limoges, Lyon, Marseille, Montpellier, Paris, Rouen
2022-05-16
By invitation
AstraZeneca
Phase 3
214
Besançon, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier, Rennes
2022-04-19
Recruiting
AstraZeneca
Phase 2
630
Avignon, Bobigny, Bordeaux, Limoges, Rennes, Rouen, Suresnes, Toulon
2022-04-14
Active, closed
AstraZeneca
Phase 3
1,035
Bordeaux, Brest, Clermont-Ferrand, Créteil, Montpellier, Paris, Rouen, Saint-Herblain
2022-03-25
Active, closed
AstraZeneca
Phase 3
363
Aurillac, Bordeaux, Marseille, Paris, Strasbourg, Toulouse
2022-02-15
Active, closed
AstraZeneca
Phase 3
1,051
Avignon, Besançon, Bordeaux, Clermont-Ferrand, Créteil, Lorient, Marseille, Montpellier
2022-02-07
Active, closed
AstraZeneca
Phase 3
148
Bordeaux, Quimper, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
454
Bordeaux, Dijon, Le Mans, Lyon, Marseille, Nantes, Toulouse, Villejuif
2021-10-28
Active, closed
AstraZeneca
Phase 3
732
Bezannes, Bordeaux, Lille, Lyon, Montpellier, Plérin, Toulouse, Villejuif
2021-10-18
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugSabestomig
AstraZeneca
Phase 1/2
136
Bordeaux, Rennes, Villejuif
2021-09-28
Active, closed
AstraZeneca
Observational
274
Abbeville, Aix-en-Provence, Angers, Antibes, Avignon, Bastia, Bayonne, Bordeaux
2021-05-12
Active, closed
AstraZeneca
Phase 3
1,157
Avignon, Besançon, Bordeaux, Caen, Le Mans, Montpellier, Nice, Paris
2021-04-26
Recruiting
AstraZeneca
Phase 1
304
Bordeaux, Dijon, Pierre-Bénite, Saint-Herblain, Villejuif
2021-03-09
Active, closed
AstraZeneca
Phase 3
1,371
Besançon, Bordeaux, Brest, Caen, Dijon, Le Mans, Lille, Montpellier
2021-01-28
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
Bordeaux, Lyon, Villejuif
2020-12-30
Active, closed
AstraZeneca
Phase 3
358
Avignon, Bordeaux
2020-12-16
Active, closed
AstraZeneca
Phase 3
370
Avignon, Bordeaux, Clermont-Ferrand, Dijon, Lyon, Marseille, Montpellier, Strasbourg
2020-10-02
Active, closed
AstraZeneca
Phase 3
866
Avignon, Besançon, Bordeaux, Brest, Caen, Dijon, Le Mans, Marseille
2020-07-24
Active, closed
AstraZeneca
Phase 3
1,012
Besançon, Bordeaux, Marseille, Montpellier, Nice, Paris, Pierre-Bénite, Quimper
2020-07-13
Active, closed
AstraZeneca
Phase 3
587
Bordeaux, Lyon, Montpellier, Villejuif
2019-07-02
Active, closed
AstraZeneca
Phase 3
1,407
Besançon, Bordeaux, Limoges, Lyon, Marseille, Nantes, Paris, Saint-Herblain
2019-01-04
Active, closed
AstraZeneca
Phase 3
1,018
Amiens, Angers, Bordeaux, Lyon, Marseille, Montpellier, Strasbourg, Suresnes
2018-05-14
Active, closed
AstraZeneca
Phase 2
273
Angers, Besançon, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier
2018-03-07
Active, closed
AstraZeneca
Phase 2
528
Bordeaux, Nantes, Paris, Villejuif
2017-12-18
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Bordeaux, Vandœuvre-lès-Nancy, Villejuif
2017-07-25
Active, closed
AstraZeneca
Phase 1
117
Bordeaux, Caen, Lyon, Marseille, Saint-Herblain, Toulouse
2016-12-28
Active, closed
AstraZeneca
Phase 1/2
264
Bordeaux, Caen, Clermont-Ferrand, Dijon, Marseille, Nantes, Paris, Pierre Benit Cedex
2016-03-17
Active, closed
AstraZeneca
Phase 3
1,126
Bordeaux, Caen, Lyon, Marseille, Paris, Poitiers, Suresnes, Toulouse
2015-11-02
Active, closed
AstraZeneca
Phase 3
1,118
Bordeaux, Brest, Créteil, Lille, Lyon, Marseille
2015-07-21
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bordeaux, Lyon, Saint-Herblain, Villejuif
2014-10-31
Active, closed
AstraZeneca
Phase 3
1,837
Avignon, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand, Dechy, La Roche-sur-Yon
2014-04-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Bordeaux, Caen, Lyon, Nantes, Paris, Pierre-Bénite, Saint-Cloud, Toulouse
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Bordeaux, Caen, Lyon, Nantes, Paris, Vandœuvre-lès-Nancy, Villejuif
2013-08-26
Rows per page Showing 1–62 of 62
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/bordeaux

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 62 of those studies with a site in Bordeaux that also match the filters currently applied.

How many clinical trials are recruiting in Bordeaux?

19 of the 62 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 42 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bordeaux), 62 studies
PhaseStudiesRecruitingShare
Phase 3431269.4%
Phase 27411.3%
Observational508.1%
Phase 1426.5%
Phase 1/2314.8%

Most active sponsors

Lead sponsors with the most studies (Bordeaux)
Lead sponsorStudiesRecruiting
AstraZeneca6219
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.